Project Grant R44HD088243

Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,024,635 project grant to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and enhance quality of life for heart failure patients by eliminating the need for a percutaneous driveline and external power supply. The key innovation is a hybrid magnetically levitated blood pump that requires...

This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...

The University of Texas at Dallas received a $608,874 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on improving outcomes for patients with ventricular assist devices (VADs). The key products and services to be delivered under this 4-year grant include: Identifying pre-implant biomarkers that can predict post-VAD implantation infection risk. Determining if the high infection rates in VAD recipients are...

Corveus Medical, Inc. was awarded a $255,841 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an extravascular bipolar catheter for targeted nerve ablation with minimal collateral damage to surrounding tissues. The grant aims to support the design and prototyping of a minimally invasive, catheter-delivered venous procedure for performing extravascular greater splanchnic nerve ablation. The proposed catheter...

Vesteck, Inc. received a $1,364,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, through May 31, 2027. The award supports development and commercialization of an endovascular suturing device designed to augment endograft fixation during endovascular repair of abdominal aortic aneurysm (AAA). The device addresses a critical clinical need by reducing reinterventions...

Federal Project Grant Award Summary Award Details: Perfusion Solutions Inc. received a $320,838 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award was obligated on September 5, 2025, with an ultimate completion date of February 28, 2027. Products and Services: The grant funds development of a fail-safe, high-output mechanical circulatory support device designed for pediatric and congenital heart...

Federal Grant Award Summary Cutcath LLC received a $395,306 Small Business Technology Transfer (STTR) Phase I project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for December 31, 2026. The company is developing and testing the Cutcath Dissection Septum Cutting Catheter (DSCC), a novel minimally invasive electrosurgical device designed to address acute aortic...

Federal Project Grant Award Summary Aust Development, LLC received a $313,302 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025 and completion target of August 31, 2026. The company will develop and deliver a novel precision lead delivery platform designed to improve cardiac conduction system (CCS) pacing procedures. The deliverables include a...

Federal Grant Award Summary Nimble Surgical Incorporated received a $314,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, through September 14, 2026. The company will develop and advance the FLEXLOCK guide catheter, a manually operable medical device featuring an innovative anchoring tip designed to provide simultaneous active and passive support for complex...